Humanized anti-CD79B antibodies and immunoconjugates and methods of use

1. An immunoconjugate comprising an anti-CD79b antibody covalently attached to a cytotoxic agent, wherein the anti-CD79b antibody comprises:

i) an HVR-L1 comprising the sequence of SEQ ID NO: 23;

ii) an HVR-L2 comprising the sequence of SEQ ID NO: 24;

iii) an HVR-L3 comprising the sequence of SEQ ID NO: 25;

iv) an HVR-H1 comprising the sequence of SEQ ID NO: 31;

v) an HVR-H2 comprising the sequence of SEQ ID NO: 32; and

vi) an HVR-H3 comprising the sequence of SEQ ID NO: 33.

2. The immunoconjugate of claim 1 , wherein the cytotoxic agent is selected from the group consisting of a toxin, a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme.

3. The immunoconjugate of claim 2 , wherein the immunoconjugate comprises Formula I

Ab-(L-D) p   I

wherein:

(a) Ab is the anti-CD79b antibody;

(b) L is a linker;

(c) D is a drug moiety; and

(d) p ranges from about 1 to about 8.

4. The immunoconjugate of claim 3 , wherein L comprises one or more of 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), bis-maleimido-trioxyethylene glycol (BMPEO), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (STAB).

5. The immunoconjugate of claim 3 , wherein D is selected from the group consisting of an auristatin, a maytansinoid, and a dolastatin.

6. A pharmaceutical composition comprising the immunoconjugate of claim 3 and a pharmaceutically acceptable carrier.

7. The immunoconjugate of claim 1 , wherein the cytotoxic agent is a drug moiety,

wherein the anti-CD79b antibody comprises a heavy chain and a light chain, and

wherein the anti-CD79b antibody comprises an engineered cysteine at one or more positions selected from the group consisting of 15, 43, 110, 144, 168, and 205 of the light chain according to Kabat numbering convention, and 41, 88, 115, 118, 120, 171, 172, 282, 375, and 400 of the heavy chain according to EU numbering convention.

8. The immunoconjugate of claim 7 , wherein the immunoconjugate comprises Formula I:

Ab-(L-D)p  I

wherein:

(a) Ab is the anti-CD79b antibody,

(b) L is a linker,

(c) D is the drug moiety, wherein the drug moiety is selected from the group consisting of an auristatin, a dolastatin, and a maytansinoid,

(d) p ranges from about 1 to about 8; and

wherein the anti-CD79b antibody is attached through the one or more engineered cysteines to the drug moiety (D) by the linker (L).

9. The immunoconjugate of claim 8 , wherein p is about 2.

10. The immunoconjugate of claim 8 , wherein L comprises the formula:

-Aa-W w -Y y -

wherein:

A is a Stretcher unit covalently attached to a cysteine thiol of the anti-CD79b antibody (Ab);

a is 0 or 1;

each W is independently an Amino Acid unit;

w is an integer ranging from 0 to 12;

Y is a Spacer unit covalently attached to the drug moiety; and

y is 0, 1, or 2.

11. The immunoconjugate of claim 10 , wherein the immunoconjugate comprises the formula:

wherein PAB is para-aminobenzylcarbamoyl, and R 17 is a divalent radical selected from the group consisting of (CH 2 ) r , C 3 -C 8 carbocyclyl, O—(CH 2 ) r , arylene, (CH 2 ) r -arylene, -arylene-(CH 2 ) r —, (CH 2 ) r —(C 3 -C 8 carbocyclyl), (C 3 -C 8 carbocyclyl)-(CH 2 ) r , C 3 -C 8 heterocyclyl, (CH 2 ) r —(C 3 -C 8 heterocyclyl), —(C 3 -C 8 heterocyclyl)-(CH 2 ) r —, —(CH 2 ) r C(O)NR b (CH 2 ) r —, —(CH 2 CH 2 O) r —, —(CH 2 CH 2 O) r —CH 2 —, —(CH 2 ) r C(O)NR b (CH 2 CH 2 O) r —, —(CH 2 ) r C(O)NR b (CH 2 CH 2 O) r —CH 2 —, —(CH 2 CH 2 O) r C(O)NR b (CH 2 CH 2 O) r —, —(CH 2 CH 2 O) r C(O)NR b (CH 2 CH 2 O) r —CH 2 —, and —(CH 2 CH 2 O) r C(O)NR b (CH 2 ) r —;

wherein R b is H, C 1 -C 6 alkyl, phenyl, or benzyl; and r is independently an integer ranging from 1 to 10.

12. The immunoconjugate of claim 11 , wherein W w is valine-citrulline.

13. The immunoconjugate of claim 11 , wherein R 17 is (CH 2 ) 5 or (CH 2 ) 2 .

14. The immunoconjugate of claim 10 , wherein the immunoconjugate comprises the formula:

wherein R 17 is a divalent radical selected from the group consisting of (CH 2 ) r , C 3 -C 8 carbocyclyl, O—(CH 2 ) r , arylene, (CH 2 ) r -arylene, -arylene-(CH 2 ) r —, (CH 2 ) r —(C 3 -C 8 carbocyclyl), (C 3 -C 8 carbocyclyl)-(CH 2 ) r , C 3 -C 8 heterocyclyl, (CH 2 ) r —(C 3 -C 8 heterocyclyl), —(C 3 -C 8 heterocyclyl)-(CH 2 ) r —, —(CH 2 ) r C(O)NR b (CH 2 ) r —, —(CH 2 CH 2 O) r —, —(CH 2 CH 2 O) r —CH 2 —, —(CH 2 ) r C(O)NR b (CH 2 CH 2 O) r —, —(CH 2 ) r C(O)NR b (CH 2 CH 2 O) r —CH 2 —, —(CH 2 CH 2 O) r C(O)NR b (CH 2 CH 2 O) r —, —(CH 2 CH 2 O) r C(O)NR b (CH 2 CH 2 O) r —CH 2 —, and —(CH 2 CH 2 O) r C(O)NR b (CH 2 ) r —;

wherein R b is H, C 1 -C 6 alkyl, phenyl, or benzyl; and r is independently an integer ranging from 1 to 10.

15. The immunoconjugate of claim 14 , wherein R 17 is (CH 2 ) 5 or (CH 2 ) 2 .

16. The immunoconjugate of claim 10 , wherein the immunoconjugate comprises the formula:

17. The immunoconjugate of claim 8 , wherein L is SMCC, SPP, SPDB, or BMPEO.

18. The immunoconjugate of claim 8 , wherein D is MMAE comprising the structure:

wherein the wavy line indicates the attachment site to the linker L.

19. The immunoconjugate of claim 8 , wherein D is MMAF comprising the structure:

wherein the wavy line indicates the attachment site to the linker L.

20. The immunoconjugate of claim 8 , wherein D is DM1, DM3, or DM4 comprising the structure:

wherein the wavy line indicates the attachment site to the linker L.

21. The immunoconjugate of claim 7 , wherein the anti-CD79b antibody is selected from the group consisting of a monoclonal antibody, a bispecific antibody, a chimeric antibody, a human antibody, a humanized antibody, and an antibody fragment thereof.

22. The immunoconjugate of claim 21 , wherein the antibody fragment is a Fab fragment.

23. The immunoconjugate of claim 8 , wherein the immunoconjugate comprises any of the following structures:

wherein Val is valine; Cit is citrulline; and p is 1, 2, 3, or 4.

24. The immunoconjugate of claim 8 , wherein L is MC-val-cit-PAB or MC.

25. A pharmaceutical formulation comprising the immunoconjugate of claim 7 , and a pharmaceutically acceptable diluent, carrier, or excipient.

26. An article of manufacture comprising:

the pharmaceutical formulation of claim 25 ;

a container; and

a package insert or label indicating that the immunoconjugate can be used to treat cancer characterized by the overexpression of a CD79b polypeptide.

27. The article of manufacture of claim 26 , wherein the cancer is selected from the group consisting of lymphoma, non-Hodgkin's lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

28. The immunoconjugate of claim 1 , wherein the anti-CD79b antibody comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 16, and a light chain variable domain comprising the sequence of SEQ ID NO: 12.

29. The immunoconjugate of claim 1 , wherein the anti-CD79b antibody comprises a heavy chain comprising the sequence of SEQ ID NO: 90, and a light chain comprising the sequence of SEQ ID NO: 89.

30. The immunoconjugate of claim 7 , wherein the heavy chain comprises the sequence of SEQ ID NO: 85, and the light chain comprises the sequence of SEQ ID NO: 86.

31. The immunoconjugate of claim 7 , wherein the heavy chain comprises the sequence of SEQ ID NO: 87, and the light chain comprises the sequence of SEQ ID NO: 88.